Why I’m fighting for renal medullary carcinoma patients

As I entered the fall of 2016, I found myself excited about my
brother Herman’s cancer-free status. He had returned from MD Anderson at the end of August with
continued good news: clear scans.

Four years ago, he was diagnosed with renal medullary carcinoma, an
extremely rare type of kidney cancer with a poor prognosis. Herman’s
been cancer-free for the last two years.

Many people are shocked when they hear Herman is still surviving.
When you read the statistics, he shouldn’t be here.

But as I’ve learned, despite your diagnosis, there’s always hope
beyond what you see.  

Don’t be afraid to reach out 

When Herman was diagnosed with renal medullary carcinoma in 2012,
our family couldn’t see a way out. All of the odds seemed stacked
against us.

To have a center of excellence like MD
accept us was such a blessing. Herman’s story brings
hope to everyone who has been diagnosed with renal medullary carcinoma.

However, the statistics are still sobering, and currently there is
no cure for renal medullary carcinoma. All of the survivors I meet are
desperate for a doctor who is familiar with treating this disease. I
feel lucky that we found Nazir Tannir, M.D., Herman’s MD Anderson oncologist, who is one of the
world’s leaders in treating renal medullary carcinoma.

Building hope through advocacy

In 2013, I established a foundation dedicated to renal medullary
carcinoma to raise awareness and educate others. I care about
educating families because I know how important early detection is.

I never thought that we would grow as much as we have over the past
three years. We have had countless renal medullary carcinoma patients
contact us from around the world. This means so much because when
Herman was diagnosed, we couldn’t find one person with the exact same diagnosis.

I remember feeling so hopeless. I didn’t want anyone to feel like
this. So I created a community through social media where others can
get connected and know that they aren’t alone.

Through this community we’ve launched a petition asking for the
President of the United States to help in ensuring that individuals
who carry sickle cell trait will be screened. I also created a
registry for doctors to analyze information about people with renal
medullary carcinoma. The goal of the registry is to gather information
that can be used to estimate the number of cases of renal medullary
carcinoma each year, estimate the number of people with renal
medullary carcinoma at a specific point in time, better understand who
gets renal medullary carcinoma and what factors affect the disease,
examine the connection between renal medullary carcinoma and those who
carry the sickle cell trait, and improve renal medullary carcinoma treatment.

One of our greatest strides thus far was helping enact a bill in my
home state of South Carolina, which required hospitals and birth
centers to provide sickle cell disease and trait education for each
newborn baby considered high-risk for renal medullary carcinoma.

Fighting for better renal medullary carcinoma research and treatment

In advocating for renal medullary carcinoma patients, we speak for
the needs of patients, survivors and the loved ones of those who have
died of this disease. In doing so, we help shape policy, research and
programs, both nationally and internationally.

Now, we’ve gone one step further and are working with Tannir through
an alliance comprised of 17 renal medullary carcinoma specialists. The
group, which Tannir co-chairs, hopes to set the stage for more renal
medullary carcinoma research and clinical trials that will help us
better diagnose and treat this rare disease.

I couldn’t have dreamed that we could have this much of an impact
when Herman was first diagnosed with renal medullary carcinoma. But as
I’ve learned, with hard work and creativity, we caregivers and
patients can make our voices heard and bring more attention and
resources to rare cancers like renal medullary carcinoma.

Request an appointment at MD Anderson online or by
calling 1-877-632-6789.